

Orchid Cancer Appeal
**Annual Report and
Financial Statements
2022–2023**

OUR IMPACT

ORCHID 
FIGHTING MALE CANCER

Orchid Cancer Appeal **Annual report and financial statements 2022-2023**

Board of Trustees

Mr CS Osborne Chair
Mr W Cohen Treasurer
Mr D Badenoch
Mr PG Bracher
Mr S Harris
Mr M Kibblewhite
Professor RTD Oliver
Mr P Norman
(resigned 21 May 2023)
Mr B Ayres
Professor P Rajan
(appointed 7 December 2023)
Mr J Shedden
(appointed 7 December 2023)

Chief Executive

Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP
6th Floor, 9 Appold Street,
London EC2A 2AP

Accountants

JS2 Limited
1 Crown Square, Woking,
Surrey GU21 6HR

Legal advisors

Farrer & Co
66 Lincoln's Inn Fields,
London WC2A 3LH

Bankers

HSBC Plc
20 Electric Parade,
George Lane,
South Woodford,
London E18 2LX

Registered Office

60 Gray's Inn Road,
London WC1X 8AQ

Tel 020 3745 7310
www.orchid-cancer.co.uk

Registered in England with the
Charity Commission No.1080540

Company Limited by Guarantee
Registered in England
No. 3963360

Inside this report:

Letter from the Chair	6
CEO's letter	7
The year in review	10
Fundraising	14
Our impact	22
Prostate cancer	22
Testicular cancer	26
Penile cancer	30
Research	32
The year ahead	36
Governance	40
Financial review	44
Formal statements	44
Independent Examiner's information	44
Independent Examiner's Report	45
Statement of financial activities	47
Balance sheet	48
Statement of cash flows	49
Notes to the financial statements	50

Letter from the Chair

Orchid has now been a charity for 26 years. We exist to save men's lives – sadly over 12,000 men in the UK lose their lives to male-specific cancers (testicular, prostate and penile) each year – yet it's a testament to our donors, fundraisers, volunteers and staff that many more are saved through awareness and early interventions.

Every year over 55,000 people are diagnosed with prostate, testicular or penile cancer and this number continues to increase.

Despite this:

- there is low awareness amongst men even those at most risk
- too many are diagnosed too late which reduces treatment options
- there are health inequalities – Black African and Black Caribbean men have an increased risk of prostate cancer
- men don't know where to turn for support on diagnosis

And so, Orchid continues to educate people about male cancers, creating understanding about who is at risk and the signs and symptoms to look out for, so as many men as possible get an early diagnosis if they need one.

Orchid's roots are in research and the research we have funded to date has helped to identify new ways to treat male cancers and improved our understanding of how male-specific cancers behave.

We continue our support for the Robert Lane Tissue Bank which is an internationally important resource for research into penile, testicular, and prostate cancer, and is led by Professor Dan Berney who is an internationally recognised pathology expert in the three male

genito-urinary cancers. We were delighted when he was chosen to deliver the Kristin Henry Lecture at the Liverpool Pathology conference in June 2023 and again when he was presented with the Cunningham Medal by the British Division of the International Academy of Pathology in November 2023.

We congratulate Professor Berney and are immensely proud to have him with us, as we are to have all our staff and supporters – the individuals who donate or participate or volunteer; the Charitable Trusts and Foundations, the National Lottery Community Fund and companies who fund our projects; our project partners who help us deliver results; our Trustees, giving their time to make sure Orchid keeps on with its mission and of course all our staff.

And finally, I would like to mention Peter Norman who stepped down as a Trustee during the year and thank him for his most wonderful service and contribution to what we have achieved.

My sincere thanks to you all

Colin Osborne MBE, Chair

Letter from the CEO

It has been another busy and productive year for Orchid. While our overall aim remains to develop innovative ways of meeting the needs of those at risk of and affected by prostate, testicular and penile cancer, we also recognise that some people face additional challenges to accessing services such as diagnosis and treatment. We aim to meet these needs by working collaboratively and thinking creatively to reach wider and new audiences, regardless of who they are, so they receive the information and support they need.

Highlights this year included:


- Male Cancer Awareness Week in September 2023, which focused on Small Change, Big Difference, helping men understand the changes in their bodies which could be a sign of male cancer.
- Our team of 85 Volunteer Community Champions did a fabulous job cascading prostate cancer messages across 10 cities outside of London.
- Funding was received to deliver a new Four Nations Penile Cancer Programme to raise the profile of penile cancer in the UK and improve support for anyone affected.
- We worked collaboratively with partners across the UK to reach marginalised communities to make sure they did not miss out on messaging about prostate, testicular and penile cancer.
- Orchid's Freephone Confidential Helpline continued to provide a lifeline to those affected by any of the cancers we cover.
- Our unique telephone counselling service enabled those affected by penile and testicular cancer to deal with the challenges of a diagnosis and treatment undergone.

- We launched Take 3 – a series of short documentary drama films introduced by the case studies themselves.
- We increased investment in research with a grant awarded for a new area of prostate cancer research.

The dedication of our staff, trustees, volunteers, patient advocates, partners and those who shared their stories enabled the charity to achieve so much.

I would like to take this opportunity to thank everyone who helped us in any way and highlight our wonderful donors. We could not have reached and supported so many people without both existing loyal and new donors whose support we really value. Thank you to each and every supporter.

Ali Orhan, CEO




33,977 people learnt about prostate cancer through the awareness interventions of Orchid Community Champions and experienced volunteers



The year in review

More than 55,000 men are diagnosed each year in the UK with prostate, testicular or penile cancer, and sadly around 12,000 die. Thankfully, however, many more will recover. To save lives, Orchid worked tirelessly throughout the year to help people better understand male cancer risk factors, potential signs and symptoms, as well as the benefits of an early diagnosis.



We were excited to launch *Take 3*, a new series of films based on real patient experiences

Through our Nurse-led services we supported those living with a diagnosis, and we continued to invest in world-class male cancer research to benefit both current and future generations.

Orchid's Male Cancer Information Nurse Specialists gave personal support and guidance about concerns, the diagnostic pathway and treatment to those who called our confidential Freephone Male Cancer Helpline. This offers a joined-up service with some callers signposted to our unique testicular and penile cancer telephone service which offers a degree of anonymity to encourage men affected by these diseases to talk openly about their fears with a professional cancer counsellor. Peer support opportunities were delivered both virtually and in person.

As cancers found early are often the easiest to treat, education and awareness was a priority, especially as male cancer awareness remains low. We had a particular focus on reaching people from marginalised communities who may miss mainstream health messaging. 5,511 people had an opportunity to learn about male cancer by attending a Male Cancer Information Roadshow delivered in settings such as shopping centres and markets and in locations from Glasgow to Hastings, and Wakefield to Slough. Others had a chance to better understand their risk and what to look out for by attending talks and question and answer sessions in community groups or via our Health at Work programme.

Trans women are also at risk of prostate cancer, and we used the learnings from a focus group we ran with a group of trans women to inform a targeted series of social media posts. We also updated our website to make it more inclusive with the support of a charity trusted by the community.



WE NEED YOU
A focus group
for trans women

Orchid wants to learn about
what trans women want to know about
prostate cancer and the type of support they need.
PLEASE REGISTER HERE

working together
Healthworks the community health charity ORCHID

The learnings from a focus group with trans women helped inform a targeted series of social media posts


We are grateful for the support we receive from volunteers who help us spread the word about male cancers. A London based volunteer reached 7,675 people with information during the year, and 26,302 people in ten different locations in England received prostate cancer information from our Volunteer Community Champions who were trained as part of our *Overcoming the Barriers to Engaging with Prostate Cancer* project. Our Champions include those with lived experience, healthcare professionals, residents in prisons and those who simply want to help.

Reaching people digitally has become increasingly effective and 2023's Male Cancer Awareness Week with its message of *Small Change, Big Difference*, and International Penile Cancer Awareness Day, were both driven by social media. In addition to the organic reach of social media during Male Cancer Awareness Week, paid advertising on Facebook enabled 236,970 people to see our message highlighting that responding to a concern about a change to your body quickly can make a big difference if cancer is detected.

Orchid's awareness activities are supported by a portfolio of online, paper based and film resources. December saw the launch of a new Orchid website to

provide more accessible information to men and their loved ones as well as to healthcare professionals. Demand for information on both the Orchid website and our Your Privates testicular cancer microsite remained high throughout the year.

We were excited to launch a new series of films called *Take 3* based on three real patient experiences to help inform men of all ages about the signs, symptoms and risk factors of prostate, penile and testicular cancers, and the need to seek help from a healthcare professional promptly if concerned. This was complemented by a new booklet describing nine real life encounters designed to get people thinking – and talking – about these male-specific cancers. Orchid had an advisory role in a short film called *Ignore It* which was produced by penile cancer survivor Mr Richard Stamp and funded by eUROGEN.



A new booklet describing nine real life encounters was designed to get people thinking – and talking – about male-specific cancers

Orchid works closely with eUROGEN a European organisation which is dedicated to improving the outcomes for rare urological conditions by enabling equitable access to diagnosis, treatment, and care for patients across Europe. Two penile cancer advocates supported by Orchid were involved in updating the current EAU Guidelines for penile cancer, a huge achievement, providing a much better recognition of the long-term issues which men may experience as a result of treatment and the need to expand the support which is currently available.

Orchid collaborated throughout the year with health and social care professionals, policy makers and other cancer charities to bring about positive change for men and their families. Examples include helping recruit Black African and Black Caribbean men to share their experience of prostate cancer on Prostate Cancer Research's new Infopool, and as part of our collaboration with the Testicular Cancer Network, Orchid Nurse Rob Cornes attended the National Germ Cell Meeting in Glasgow attended by around 130 clinicians and specialist nurses where he helped chair a session on how members are working together to save lives.

Funding research is vital to help understand why men develop male cancers and to improve the way in which they are diagnosed and treated. Orchid continued support for the Robert Lane Tissue Bank which is led by Professor Dan Berney whose work is focused on the pathology and natural history of prostate, testicular and penile cancer, translating basic research into practical treatments for patients with novel tests and bespoke predictive treatments. A grant was also agreed for new prostate cancer research to be funded by donations to the Innovation Research Project and which will begin in the new financial year.



December saw the launch of Orchid's new website to provide more accessible information to men and their loved ones as well as to healthcare professionals





350,906 accounts were reached through Orchid's five social media platforms

Fundraising

Orchid is committed to fundraising from diverse income streams to ensure adequate income is received to fund our work to save lives from prostate, testicular and penile cancers. A total of £730,024 was raised during the year, and we thank each and every one of our wonderful supporters who gave during the financial year, be they individuals, community groups, sports clubs, schools, companies, charitable trusts and foundations or The National Lottery Community Fund.



A new fundraising leaflet was developed to encourage donations

So many people supported Orchid during the year because they have been touched by male cancer themselves, or they raised funds in memory of loved ones. Payroll giving and both new and regular donors provided a valuable source of unrestricted income, as did the gifts given in Wills. A new fundraising leaflet was developed to encourage donations.

It is quite humbling to view people's dedication to our cause. This is why the Orchid team were there to cheer participants on at major events such as the London Marathon and Landmarks Half Marathon, as well as at Orchid's own events including our first Willy Waddle in Edinburgh and one in London. Our small fundraising team also helped and encouraged our many supporters from right across the UK who organised so many different fundraising activities such as cake sales, the Twyford



Orchid team were there to cheer on participants at major events such as the London Marathon and Landmarks Half Marathon

Beer Festival, a large beard competition, a new 'Bollox and Boots' event, a classic car event, or who challenged themselves via cycling, walking, climbing, or running events. Each person helped Orchid to make a difference.

There were some significant grants received during the year from Charitable Trusts and Companies towards delivering Nurse-led services to support those affected, to raise awareness through Male Cancer Information Roadshows in the heart of local communities, in faith settings and via social media, to develop new films, and to fund a new Four Nations Penile Cancer Programme to start in the new financial year. Funding was also received to fund male cancer research.

Incorporating learnings is important across the charity. Throughout the year Orchid staff and Trustees continued to review our fundraising activities and sought to identify new opportunities to ensure we retain as diverse and cost-effective fundraising base as possible to balance risk in the years ahead.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and putting supporters at the heart of all we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies. Orchid operates a clear and stringent complaints handling procedure that is reported to the Chief Executive and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to

help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

During the year we did not receive any complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

Small Change, Big Difference

Orchid’s Male Cancer Awareness Week successfully raises the profile of prostate, testicular and penile cancer each year. In 2023 it was launched by Orchid Patron Steve Davis OBE, and included a fundraising ask for the first time.

The Week was themed *Small Change, Big Difference* and was delivered mainly digitally. Posts about each male-specific cancer across all social media platforms throughout the Week highlighted the small changes to men’s bodies which could be a symptom of that cancer.

As well as highlighting the difference an early diagnosis can make, the posts also showed the difference making a donation or giving your small change to Orchid would make, linking donations to the Nurse-led services and the male cancer research the charity funds.

It also provided an opportunity for supporters to fundraise under the umbrella of Small Change, Big Difference.



Prostate Cancer
hesitancy 52,000 cases
urgency weak flow
frequency

Small change

Big difference
information
funding vital research
awareness
education
helpline
counselling

ORCHID 
FIGHTING MALE CANCER

Make a big difference by donating this awareness week


 Financially supported by THE FINANCIAL CONDUCT AUTHORITY REGULATOR
Registered in England No. 10002940
Company Registered in England No. 3963360

orchid-cancer.org.uk

Male Cancer Awareness week
11th - 17th September 2023

Orchid's Male Cancer Awareness Week provided an opportunity for supporters to fundraise under the umbrella theme of *Small Change, Big Difference*





32,691 male cancer leaflets, booklets and posters were ordered or requested by individuals, companies, educators, and healthcare professionals

Our impact:

Prostate cancer

Over 52,000 people are diagnosed with prostate cancer in the UK annually, that's more than 140 every day. Sadly, there are 11,855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, 1 in 6 UK males (born in the 1960s) will be diagnosed with prostate cancer in their lifetime, although the most commonly accepted statistic for general risk remains 1 in 8.

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those who may be at risk of disease progression and those with mild or inactive disease. One of the interesting directions that this may take is so called liquid biopsies – the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

In addition, those men with minimal risk of disease progression are likely to be managed by active surveillance. This is an option that is likely to increase dramatically over the next few years and one which Orchid has already created information about. Some men who are put on active surveillance may take 6-months or more to adjust to the fact that their cancer does not require immediate treatment and Orchid has responded to the need for information and support to help them.

One of the greatest challenges around prostate cancer remains the unequal risk of this cancer among Black African and Black Caribbean men who are twice as likely to develop prostate cancer than Caucasian men. Creating awareness in this community and helping support Black men diagnosed with prostate cancer is crucial. Although there are more than a hundred prostate cancer support groups in the UK, the Black community remains underrepresented.

A need also exists to reach trans women and non-binary people assigned male at birth with prostate cancer messaging, as they too can be diagnosed with this cancer.



Spotlight on Let's Talk Prostate Cancer Campaign

One in four Black African and Black Caribbean men will get prostate cancer in their lifetime, compared to one in eight Caucasian men, and tackling health inequalities is at the heart of Orchid's work.

Orchid was therefore proud to be invited by Astellas Pharma Limited to host a parliamentary workshop to hear from Black African and Black Caribbean men who are living with prostate cancer about their personal experiences of care.

The voices of these men informed the writing of the report *'1 in 4 Black men. Turning the tide on health inequalities in prostate cancer care'* with its important recommendations which are being considered by national parliamentarians and policy makers.

The workshop took place in March 2023 and all men present spoke with great passion about their prostate cancer journeys. Whilst there were many different experiences expressed, there was complete consensus that health inequalities associated with prostate cancer are not adequately prioritised or given the attention they should be.

Attendees felt men from diverse backgrounds could not easily engage with public prostate cancer messaging, and that they were not involved in their development. They found that the 1 in 4 statistic is not

sufficiently prominent. Messaging does not feature Black African and Black Caribbean men in images and it lacks cultural awareness/sensitivity. Furthermore, the men felt that the stigma around prostate cancer diagnosis and the use of a Digital Rectal Examination, and the potential side effects of treatment, which could both be barriers to engaging, have not been adequately addressed. Also expressed were the difficulties encountered asking GPs for a PSA test, which were often only offered based on age even when men highlighted their increased risk/family history.

Men also shared that there is a lack of easy to understand and culturally appropriate information at the point of diagnosis. This led to a lack of understanding about their treatment pathway and any potential side effects of treatment, and when they expressed a treatment preference, they felt their views were not always listened to and felt under pressure to have certain treatment.

The report, written taking the view of these men into account along with research of the prostate cancer policy landscape, sets out key recommendations to help push prostate cancer and the unequal risk of Black men up the agenda. The report has been well received and the recommendations are currently being discussed with parliamentarians and policy makers.



7,041 people had a one-to-one interaction with Orchid Community Champion or volunteer



Our impact:

Penile cancer

Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.

Out of the three male-specific cancers, penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function.

Due to its intimate nature up to 50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics.

Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease - many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its rarity therefore missing out on invaluable peer support.

In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral. Orchid has therefore focused on the development of a telephone

counselling service to support men and wherever possible has created events to offer peer support, as well as supporting and encouraging allied healthcare professionals in the creation of regional support groups.

With 83 cases a year, there is a higher incidence of penile cancer in Scotland in comparison to the rest of the UK, and those affected by penile cancer in Scotland are also being diagnosed at a younger age. A penile cancer diagnosis can be psychologically devastating, and treatment can be challenging especially if the diagnosis has been made at a late stage. Orchid has significant experience of educating people about the signs and symptoms of penile cancer, as well as understanding the complex issues involved in supporting penile cancer patients.

Whilst we do not as yet know why Scotland has a higher incidence proportionally than the rest of the UK, we do know that many people have not heard of penile cancer, let alone know what potential symptoms might be. This is why Orchid identified the need to deliver a project to put penile cancer on the agenda in Scotland, and whilst delivery of this specific piece of work is complete, many of the elements have now been brought into Orchid's core services.

We are delighted that funding has been received to deliver the Four Nations Penile Cancer programme from October 2023. The aim of this Nurse-led initiative is to raise the profile of penile cancer in the UK and improve support for anyone who has been affected by the disease.



Spotlight on Penile cancer animation for EAU

Over the last few years, Orchid Nurse Rob Cornes has been working collaboratively with both the European Reference Network for Rare Urogenital Disease (ERN eUROGEN) and the European Association of Urology Patient Advocacy Group (EAU EPAG), part of the EAU Patient Office initiative.

The Patient Office is dedicated to promoting advocacy for patients being treated for urological conditions. Rob is a patient advocate for testicular and penile cancer for both these groups.

Last year with the help of Orchid, the EAU Patient Office received funding from eUROGEN to create an informative animated video discussing penile cancer to complement the EAU video library of urology.


A script was written by Orchid Nurse Rob which was then reviewed by three urology consultants specialising in penile cancer treatment. Once the script had been finalised it was also reviewed by a lay person panel and then put into production.

The aim was to include both an informative and honest overview of penile cancer diagnosis and treatment, as well as information about potential side effects in lay person's terms. It describes the most common approach to diagnosing and treating penile cancer.

Rob was particularly delighted to be able to include a section which promotes the need for men diagnosed with penile cancer to obtain psychological support.

As part of the funding a Spanish language version was also created.

Both animations have proved extremely popular with a combined viewing of around 20,000 views, as well as over 50 positive comments from both urologists and patients who have viewed it.



5,511 people had the opportunity to learn about male cancer by attending an Orchid Male Cancer Information Roadshow.




Our impact: Testicular cancer

Testicular cancer is rare with around 2,300-2,400 diagnoses each year in the UK. Around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of those diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks. As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects, chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment to life following treatment. Many men will only realise the full implication of their cancer journey when treatment ends and may not be able to access either peer support or psychological support.

Orchid has consistently supported the biggest testicular cancer support group in the UK, which is coordinated by several Specialist Nurses in London, both physically and virtually. In addition, the creation of Orchid's telephone counselling service allows men to access psychological support without the necessity of waiting for extended periods of time. Orchid also continues to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the UK.



Spotlight on The Know Your Body Project

Partnership working is important for Orchid to ensure we reach as many people as possible at risk of testicular cancer. The charity was therefore proud to work collaboratively with Ansar Projects and CoppaFeel! to create a series of accessible resources about testicular and breast cancer for people with learning disabilities.

49% of all deaths in people with a learning disability are deemed to be avoidable and 8% of these deaths were caused by cancer (The London King's College Learning from Lives and Deaths – People with a learning disability and autistic people LeDeR 2021 report).

The 'Know Your Body' resources were launched in October 2022 and are the first of their kind. These new resources were developed in response to the need for information for people with a learning disability to know their body and to seek medical advice when they notice changes at an earlier stage.

They include accessible testicular and breast cancer information packs, self-checking cards, testicular and breast cancer symptom guides, self-checking social stories and information on what to expect if you notice a change.

The 'Know Your Body' accessible resources were shortlisted as a finalist in the Breaking Down Barriers award at the 2023 National Learning Disabilities and Autism Awards.

We were also pleased that the resources were referenced in the *Learning from lives and deaths – People with a learning disability and autistic people (LeDeR) Action from learning report 2022/23*, taking the resources to a wider audience.

Our impact: Research

Orchid was pleased to continue to support the work of the Robert Lane Tissue Bank during the year.

Highlights of the year

Over 30 papers were published from the group in the year. Many of these relate to work done on tissue from the Robert Lane Tissue Bank in the past and donated over 10 years ago yet still in clinical use. Professor Berney now has over 300 papers.

Prostate cancer

In collaboration with Professor G Attard at University College London the team have processed 700 cases from the groundbreaking STAMPEDE clinical trial which aims to assess new treatment approaches for people affected by high-risk prostate cancer. Ms Larissa Mendez who is a histopathologist passed her PhD in September 2023 on this cohort and numerous publications are planned.

Further work continues to be published from the Trans-Atlantic prostate group cohort into early-stage prostate cancer, with a publication on how best to measure the size of prostate cancer in biopsies that will affect management.

The team are delighted to announce a collaboration with the Institute of Cancer Research to collect further samples of prostate cancer from recent clinical trials. This will support Orchid work and will focus (among others) on the PACE-B trial which found that men undergoing treatment for prostate cancer could be safely given far less radiotherapy.

Testis cancer

The main success of the year in the field of testis cancer was the publication of the first paper from the collaboration with a team at the University of Copenhagen in Denmark into risk factors to predict whether testis cancer will come back and whether chemotherapy should be offered in seminoma (a common type of testis cancer). This paper was published in September 2023 in the highly prestigious Journal of Clinical Oncology. This work will directly affect the decisions on who gets chemotherapy after removal of the cancer in surgery. This figure from the paper shows how testicular seminoma can be stratified into separate groups. The low-risk groups can be treated expectantly while the high risk groups might consider chemotherapy. Professor Berney is lead for the testis International Collaboration on cancer reporting. This work ensures that pathology reports on testis cancer are standardised worldwide.

With the support of both the Genito-Urinary Pathology Society (GUPS) and the International Society of Urological Pathologists (ISUP), Professor Berney has set up a new group to examine the 'sex cord stromal tumours' of the testis. These rare tumours are not well understood, may be malignant and are resistant to treatment. He is the lead on an international meeting in Baltimore in 2024 about these tumours and hopes to make advances in this challenging area.

The Robert Lane Tissue Bank is led by Professor Dan Berney who is one of the world's leading genito-urinary pathologists. The Tissue Bank carries out translational work which aims to link molecular and pathological data with clinical trials. The aim of the team is to curate a bespoke Tissue Bank concentrating on the three male cancers. In summary, it:

- holds over 9,000 male-specific cancer tissue samples to facilitate understanding of prostate, testicular and penile cancers, from the potential causes, through to how they are diagnosed, treated, and possibly prevented.
- houses one of the largest collections of penile cancer tissues in Europe, one of the largest testicular tissue banks in the world, and is custodian of the largest series of untreated prostate cancers globally.
- collaborates with research on an international scale, as well as conducting its own pathological and molecular research into penile, prostate, and testicular cancer.
- works in collaboration with other Orchid funded research projects.
- is committed to the ethical collection, processing, and storage of samples. Renewal of their research ethics is due in 2024.
- has major external collaborations with prestigious research bodies such as The Institute of Cancer Research, The Rigshospitalet in Denmark, University College London, Memorial Sloan Kettering Hospital, Indiana University Hospital, The Cleveland Clinic, and The Karolinska Institute.
- is a valuable source of information for students and specialist researchers wanting to learn more about male cancers; as well as being accessible to lay visitors.
- focuses on samples where outcome data is available from clinical trials. Advances in technology increasingly allow high quality sequencing and molecular work in these media.

Professor Dan Berney

- Professor Berney is Editor in Chief of Histopathology, a leading journal in the field. He is Past Secretary of the International Society of Urological Pathologists (ISUP), Past Secretary and President of the British Society of Urological Pathologists (BAUP) and Past International Secretary of the British Division of the International Academy of pathologists (BDIAP).
- He is the expert pathology lead on testis for the European Association of Urology and helping with their clinical guidance.
- He has received from the International Society of Urological Pathology, The Gleason Medal, and from the British Division of the International Association of Pathology, he received the Cunningham Medal in November 2023.
- Professor Berney was co-editor of the 5th edition of the classification of GU-tumours and led on the testis classification for the World Health Organisation.
- He has a strong social media presence being one of a select number of uro-pathologists with over 3,000 followers @daniel_berney. He has lectured throughout the world, especially in the USA and also Africa, to improve prostate cancer diagnosis.
- He is Visiting Professor at Manipal Medical College in India and has been invited to be Visiting Professor at the Cleveland Clinic in Ohio.
- Professor Berney has over 300 peer reviewed publications and numerous book chapters on urological pathology. He has an H score of 84 (i.e. he has published 84 articles each of which has been cited at least 84 times) and his work has been cited over 15,000 times. Furthermore, he had 23 publications in the last 18 months.

Professor Yong-Jie Lu

- Professor Yong-Jie Lu whose work Orchid has previously supported is the scientific lead on the Robert Lane Tissue Bank Governance Committee.
- He has supervised the day-to-day running and maintenance in the past year, while running his research team on prostate cancer circulating biomarker development.





33,100 male cancer leaflets, booklets and posters were distributed through awareness activities such as Roadshows, Volunteer Community Champion community outreach, talks and presentations

The year ahead

Cancers diagnosed at an early stage are more likely to be treated successfully which means that raising awareness of the risk factors, signs and symptoms and the benefits of an early diagnosis remained a priority as we entered the new financial year. All work will be delivered in line with our organisational Strategy October 2022 to September 2026. Funding has been received and plans are in place to deliver several new and transformational initiatives, and to further develop existing work.

Keeping the faith

We will be working with faith leaders in London to raise awareness of prostate cancer amongst the Black African and Black Caribbean men in their congregations who are at increased risk of this cancer and we will equip them to better support those living with a diagnosis. We are also planning a social media campaign around the theme of “Warn a Brother” to encourage Black African and Black Caribbean men to share information about prostate cancer with their friends and family.

Orchid on film

Films are in development to highlight prostate cancer and to get people talking about this cancer which affects over 52,000 people each year. We will also increase our outreach to trans women to make sure they gain a better understanding of their prostate cancer risk and know the support and information available to them including from Orchid.

On the road again

Male Cancer Information Roadshows are an established part of our community outreach, through which we take information right into the heart of communities. These will be delivered in targeted communities as funding becomes available. We will continue to offer male cancer talks and presentations to community groups and one priority for the year will be to deliver talks to the Deaf community supported by a British Sign Language interpreter to reduce inequality.

We are the champions

We will also continue to recruit, train and support Volunteer Community Champions as part of the National Lottery Community Fund project “Overcoming the Barriers to Engaging with Prostate Cancer”. Our Champions cascade important messages in their own

communities and workplaces, and we will explore how this work can be sustainable after funding for the project ends in May 2024, including upskilling Champions further about testicular and penile cancer alongside their knowledge of prostate cancer. Independent evaluation has been running throughout the project, and learnings will be shared with stakeholders and interested parties via a report after the project ends.

A week and a day

Orchid’s Male Cancer Awareness Week will take place between 16-22 September 2024, with International Penile Cancer Awareness Day on 20 September 2024.

Helpline focus

Supporting those affected by male cancer is also a high priority for the coming year. We are exploring increasing the hours of our Freephone National Male Cancer Helpline with the aim of missing fewer calls. Our commitment to delivering and co-facilitating peer support opportunities both in person and virtually remains, and we will continue to offer a telephone counselling service to those affected by penile or testicular cancer.

Four Nations

A new Four Nations Penile Cancer Programme started at the beginning of October led by Sinéad Collins who joined Orchid as a Male Cancer Information Nurse Specialist – Penile Cancer. Through this programme we will raise the profile of penile cancer in the UK and improve support for anyone who has been affected by the disease.

Improved patient journey

Orchid Nurse Rob Cornes will continue to work with healthcare professionals both in the UK and beyond to improve the patient journey for those affected by male

cancer. Orchid resources and services will be promoted throughout the year to healthcare professionals working in the relevant fields throughout the UK. Rob Cornes plans to work with the Testicular Cancer Network to produce an evidence-based guideline for testicular self-examination in the coming year.

Supported by penile cancer patient advocates, Rob Cornes, who is a member of the European Association of Urology Patient Advocacy Group and the European Reference Network eUROGEN European Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will continue to work to improve the patient experience for those affected by these two rare cancers. This work will include being involved in the updating of the European Association of Urology Testicular Cancer Guidelines as a patient advocate.

More social

Social media will be used to relay male cancer messages, promote our educational films, to drive followers to the Orchid website / Your Privates testicular cancer microsite, to view, order or download resources and to help promote fundraising activities. The number of followers on all platforms has increased, and we aim to grow this further. Activity is planned incorporating learnings of the last year where we saw most reaction in response to personal stories and awareness.

Rooted in research

Orchid's roots are in male cancer research, and we will continue to invest in innovative research. Trustees have agreed new funding for the year for the Robert Lane Tissue Bank, led by Professor Dan Berney MB B Chir, MA, FRCPath which is an internationally important resource for research into penile, testicular, and prostate cancer. Funding has also been agreed for new research into the characterisation of the anaerobic microbiome

and genomic methylation status of prostate cancer patients experiencing active Vitamin D and K2 deficiency: prevention, risk stratification, diagnosis, and treatment potential, led by Dr Belinda Nedjai.

Measuring up


In the coming year we will be working to improve the way in which we measure activities and their impact so we can better evidence the difference our work makes.

Orchid recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Diverse income streams

Led by a new Head of Fundraising, our fundraising strategy for 2023-2024 will focus on generating income from diverse income streams to secure adequate funding at the best possible return on investment to ensure we can deliver plans for the years ahead. We will also explore new income generating opportunities and encourage people to take part in our unique Willy Waddles planned for Edinburgh and London in the summer months. Applications will be submitted to Charitable Trusts and Foundations on a rolling basis, carrying out research to identify new potential supporters. We will work in partnership with our corporate supporters to meet their needs as well as Orchid's.

Orchid's work is only possible because of the generosity of our supporters, and we will look after them in every way we can. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf. We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead.

A photograph of a workshop or construction site. In the foreground, a person's hands are visible, operating a power tool (possibly a sander or drill) on a wooden surface. The workbench is cluttered with various tools, including a hammer, a pencil, and a small container. In the background, several power drills are lined up on a long wooden table. The wall behind the table is made of red bricks. The overall scene is brightly lit, suggesting an indoor workspace.

2,893 men, women and healthcare professionals had in-depth support or information directly from an Orchid Nurse / Male Cancer Information Manager



Governance

Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.

Objects, operating context and activities

Objects

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing.

Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and

information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair's aim to maintain a balanced composition. Trustees acknowledge the need to increase diversity on the Board and are exploring the best ways to do this. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed.

Trustees continued to meet virtually for most meetings held during 2022-2023.

Trustee training and induction

On appointment, Trustees are offered a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a report to the Board at each of its meetings. As at 30 September 2023, it comprised the Honorary Treasurer, Mr W Cohen,

Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris.

- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept apprised of personnel, awareness, research programme and budgetary issues.

Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation's strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, a Scientific Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identifies risks under the following headings:

Governance and compliance

Operational

Financial

Research

Environmental/external

Quality assurance

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not

less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are as follows:

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

Mitigation

- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
- Training and support for Board of Trustees and Finance Committee
- Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
- Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

- Annual salary review to include benchmarking of compensation and benefits
- Staff development, training and succession planning programmes
- Communication programme to ensure staff are involved in the development of and progress towards Orchid's strategy and annual workplan

Financial

Economic pressures, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

Mitigation

- Annual budgeting and ongoing management, reporting and monitoring of financial performance
- Diversification of income streams
- Ongoing consideration of market and consumer trends and regulations including GDPR

Research

Orchid's Research Programme fails to deliver results

Mitigation

- Scrutiny and approval of research funding applications by an expert Scientific Advisory Board
- Annual review of progress

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid's work

Mitigation

- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
- Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
- Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid's strategy

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

- Services developed, delivered and evaluated in line with agreed protocol and standards
- Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
- All information materials and content regularly reviewed and updated
- High-quality training for staff

Financial review

Results for the year

Income for the year ended 30 September 2023 totalled £730,024 (2022: £841,808). After total expenditure of £634,721 (2022: £740,252), the year's activities show a net surplus of £95,303 (2022: surplus of £101,556). Total reserves at the end of the year amounted to £637,139 (2022: £541,836).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity's core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible and intangible fixed assets are £157,287 (2022: £162,113). It is the Charity's policy to maintain free reserves of approximately 3–4 months of operating costs. At current levels of expenditure this equates to £155,000–£212,000.

Formal statements Statement of Trustees' responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiner's information

So far as each of the directors at the time the Trustees' report is approved is aware:

- a) there is no relevant information of which the examiner is unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees

C S Osborne
Chairman of Trustees
12/06/24

Independent Examiner's Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2023.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ("the 2006 Act").

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ("the 2011 Act"). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145 (5) (b) of the 2011 Act.

Independent examiner's statement

Since the Company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Moore Kingston Smith LLP

Adam Fullerton FCA DChA

Date: 19 June 2024

For and on behalf of
Moore Kingston Smith LLP
Chartered Accountants
6th Floor, 9 Appold Street,
London
EC2A 2AP

Statement of financial activities

(incorporating an income and expenditure account)

For the year ended 30 September 2023

	Note	Unrestricted Total £	Restricted Total £	Year ended 30 September 2023 £	Year ended 30 September 2022 £
Income from:					
Donations and Legacies	2	310,632	257,150	567,782	674,700
Charitable Activities	4	-	160,850	160,850	166,673
Trading Activities		272	-	272	309
Investment income		1,120	-	1,120	126
Total income		<u>312,024</u>	<u>418,000</u>	<u>730,024</u>	<u>841,808</u>
Expenditure on:					
Raising funds					
Fundraising (donations and grants)	5	163,449	-	163,449	185,431
Charitable Activities					
Education and Awareness	5	131,385	288,636	420,021	376,842
Research	5	15,605	35,646	51,251	177,979
Total expenditure		<u>310,439</u>	<u>324,282</u>	<u>634,721</u>	<u>740,252</u>
Net income / (expenditure) and net movement in funds	5,6	1,585	93,718	95,303	101,556
Reconciliation of funds					
Total funds brought forward		<u>297,016</u>	<u>244,820</u>	<u>541,836</u>	<u>440,280</u>
Total funds carried forward		<u>298,601</u>	<u>338,538</u>	<u>637,139</u>	<u>541,836</u>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 14 to the financial statements.

Balance sheet

As at 30 September 2023

	Note	£	30 September 2023 £	£	30 September 2022 £
Fixed Assets					
Tangible Assets	10		3,340		3,891
Intangible fixed assets	11		16,166		9,204
Current Assets					
Cash at bank and in hand		630,903		590,444	
Debtors	12	67,957		108,806	
		698,860		699,250	
CREDITORS					
Amounts due within one year	13	(81,227)		(170,509)	
Net Current Assets			617,633		528,741
Total Assets less Current Liabilities	14		637,139		541,836
NET ASSETS			637,139		541,836
Represented by:					
General Unrestricted Funds		176,793		175,208	
Designated Funds		121,808		121,808	
			298,601		297,016
Restricted funds			338,538		244,820
			637,139		541,836

The company is limited by guarantee.

For the year ending 30 September 2023 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 12/06/24 and signed on its behalf by:



Mr C S Osborne
Company number 3963360

Statement of cash flows

For the year ended 30 September 2023

	2023		2022	
	£	£	£	£
Cash flows from operating activities:				
Net income for the year	95,303		101,556	
Adjustments for:				
Depreciation charges	5,338		1,944	
Interest	(1,120)		(126)	
Decrease / (increase) in debtors	40,849		(31,481)	
(Decrease) / increase in creditors	(89,282)		21,639	
Net cash provided by operating activities	51,088		93,532	
Cash flows from investing activities:				
Interest	1,120		126	
Purchase of fixed asset	(11,749)		(12,068)	
Net cash (used in) investing activities		(10,629)		(11,942)
Change in cash and cash equivalents in the year		40,459		81,590
Cash and cash equivalents at the beginning of the year		590,444		508,854
Cash and cash equivalents at the end of the year		630,903		590,444
Analysis of cash and cash equivalents				
Cash at bank and in hand		630,903		590,444
		630,903		590,444

Notes to the financial statements

1. Accounting policies

For the year ended 30 September 2023

Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements. In particular the trustees have considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2023/24 however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its financial statements.

The trustees confirm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its financial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment - 33 $\frac{1}{3}$ % on written down value.

Intangible fixed assets and Amortisation

Intangible fixed assets and Amortisation
Intangible fixed assets are included in the balance sheet at original cost less accumulated amortisation.

Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use. Assets are amortised at the following rate:

Website - 20% on straight line value

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been

allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

Pension Scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

2. Donations

Current year	Restricted	Unrestricted	Year ended 30 September 2023	Year ended 30 September 2022
	£	£	Total £	Total £
Individuals	500	57,512	58,012	186,887
Legacies	-	19,147	19,147	100,000
Corporates	-	76,601	76,601	36,814
Trusts and Foundations	256,650	7,978	264,628	209,721
Fundraising Events	-	149,394	149,394	141,278
Total	257,150	310,632	567,782	674,700
Prior year	Restricted	Unrestricted	Year ended 30 September 2022	
	£	£	Total £	
Individuals	68,800	118,087	186,887	
Legacies	-	100,000	100,000	
Corporates	-	36,814	36,814	
Trusts and Foundations	165,121	44,600	209,721	
Fundraising Events	-	141,278	141,278	
Total	233,921	440,779	674,700	

3. Fundraising events

Current year	Year ended 30 September 2023			Year ended 30 September 2022
	Restricted £	Unrestricted £	Total £	Total £
Cycling events	-	2,296	2,296	658
Running events	-	68,852	68,852	68,646
Third party organised events	-	63,886	63,886	62,806
Trek	-	92	92	-
Other	-	14,268	14,268	9,168
Total	-	149,394	149,394	141,278

Prior year	Year ended 30 September 2022		
	Restricted £	Unrestricted £	Total £
Cycling events	-	658	658
Running events	-	68,646	68,646
Third party organised events	-	62,806	62,806
Other	-	9,168	9,168
Total	-	141,278	141,278

4. Charitable activities

Current year	Year ended 30 September 2023			Year ended 30 September 2022
	Restricted £	Unrestricted £	Total £	Total £
The National Lottery Community Fund RC England-wide	160,850	-	160,850	166,673
Total	160,850	-	160,850	166,673

Prior year	Year ended 30 September 2022		
	Restricted £	Unrestricted £	Total £
The National Lottery Community Fund RC England-wide	166,673	-	166,673
Total	166,673	-	166,673

5. Total expenditure

	Cost of raising funds £	Education and Awareness £	Research £	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Grants	-	-	18,519	18,519	149,222
Staff costs	80,542	162,814	21,298	264,654	240,059
Fundraising expenses	39,663	-	-	39,663	68,941
Information materials	-	126,256	-	126,256	98,605
Direct costs	-	33,511	-	33,511	38,393
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
	120,205	322,581	39,817	482,603	595,220
<i>Support costs</i>					
Depreciation	1,499	3,443	396	5,338	1,944
Other	33,124	76,047	8,759	117,930	117,654
Governance - staff costs	6,725	13,596	1,778	22,099	18,936
Governance - examiners fees	1,896	4,354	501	6,751	6,498
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
	43,244	97,440	11,434	152,118	145,032
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
Total expenditure	163,449	420,021	51,251	634,721	740,252
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
Prior year	185,431	376,842	177,979	740,252	

6. Grants awarded

	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Grant commitments brought forward	126,617	87,576
Institutional grants for medical research awarded during year/period		
Orchid Study and Travel Awards (2023: 2 individuals, 2022: 2 individuals)	1,000	2,000
Barts and London School of Medicine	35,646	144,652
Write off	(18,128)	
Payments made during period/year	(108,489)	(107,611)
Grant commitments carried forward	36,646	126,617
	<hr/>	<hr/>
Payable less than one year	36,646	126,617
Payable two to five years	-	-

7. Net expenditure for the period

This is stated after charging:	Year ended 30 September 2023	Year ended 30 September 2022
	Total £	Total £
Depreciation	2,400	1,944
Independent examiners' remuneration:		
Independent examination	5,435	5,415
Trustees' remuneration	Nil	Nil

8. Staff costs and numbers

Staff costs were as follows:	Year ended 30 September 2023	Year ended 30 September 2022
	Total £	Total £
Salaries and wages	235,955	205,290
Social security costs	18,666	16,414
Pension contributions	2,122	1,616
	256,743	223,320
Consultant costs	30,010	35,675
Total cost	286,753	258,995

During the year ended 30 September 2023, 1 employee earned more than £60,000 (Year to 30 September 2022: 1). The pension contribution paid in respect of this employee totalled £Nil (2022: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive.

The charity trustees do not receive remuneration. The total remuneration of the chief executive was £83,579 (year ended 30 September 2022: £78,802).

The number of employees whose emoluments amounted to over £60,000 in the year (exclusive of employer pensions and employer National Insurance contributions) was as follows:

	2023 No.	2022 No.
£60,000–£69,999	-	1
£70,000–£79,999	1	-

The average number of employees during the year was 7.4 (2022: 7.5)

The average number of employees during the year on a headcount basis was as follows:

	2023 No.	2022 No.
Fundraising	1.7	1.7
Education and Awareness	5.4	5.5
Grant support	0.3	0.3
Overall average	7.4	7.5

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fixed assets

	Computer and office equipment	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Cost			
At the start of the period	10,179	10,179	7,315
Additions	745	745	2,864
At the end of the period	10,924	10,924	10,179
Depreciation			
At the start of the period	6,288	6,288	4,344
Charge for Period	1,296	1,296	1,944
At the end of the period	7,584	7,584	6,288
Net book value			
At the end of the period	3,340	3,340	3,891
At the start of the period	3,891	3,891	2,971

11. Intangible fixed assets

	Website development	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
Cost			
At the start of the period	9,204	9,204	-
Additions	11,004	11,004	9,204
At the end of the period	20,208	20,208	9,204
Amortisation			
At the start of the period	-	-	-
Charge for Period	4,042	4,042	-
At the end of the period	4,042	4,042	-
Net book value			
At the end of the period	16,166	16,166	9,204
At the start of the period	9,204	9,204	-

12. Debtors

	Year ended 30 September 2023	Year ended 30 September 2022
	Total £	Total £
Prepayments	7,439	10,071
Other debtors and accrued income	60,518	98,735
	<u>67,957</u>	<u>108,806</u>

13. Creditors: amounts due within one year

	Year ended 30 September 2023	Year ended 30 September 2022
	Total £	Total £
Grants Payable	35,646	126,617
Trade and Other Creditors	11,424	11,113
Accruals	34,157	32,779
	<u>81,227</u>	<u>170,509</u>

14. Movements in funds

	Brought forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	175,208	312,024	(310,439)	176,793
Designated – Development	121,808	-	-	121,808
Total unrestricted	<u>297,016</u>	<u>312,024</u>	<u>(310,439)</u>	<u>298,601</u>
Restricted				
The National Lottery Community Fund - Overcoming the Barriers	40,796	160,850	(172,616)	29,030
Male Cancer Nurse Information Specialist	3,600	16,000	(19,600)	-
The Innovation Research Project	154,180	1,957	-	156,137
Penile Cancer Peer Support	1,000	760	(195)	1,565
Education and Awareness	33,655	19,858	(49,513)	4,000
Student Study and Travel Scholarships	4,729	-	(1,000)	3,729
Roadshows	6,860	37,875	(44,735)	-
Robert Lane Tissue Bank	-	48,700	(35,646)	13,054
Nurse Led Services	-	2,000	-	2,000
Four nations penile cancer programme	-	130,000	(977)	129,023
Total restricted	<u>244,820</u>	<u>418,000</u>	<u>(324,282)</u>	<u>338,538</u>
Total funds	<u>541,836</u>	<u>730,024</u>	<u>(634,721)</u>	<u>637,139</u>

14. Movements in funds (continued)

Prior year movements in funds	Brought forward £	Income £	Expenditure £	Carried forward £
Unrestricted				
General	157,158	441,214	(423,164)	175,208
Designated – Development	121,808	-	-	121,808
Total unrestricted	<u>278,966</u>	<u>441,214</u>	<u>(423,164)</u>	<u>297,016</u>
Restricted				
The National Lottery Community Fund - RC England-wide	32,445	166,673	(158,322)	40,796
Male Cancer Nurse Information Specialist - other funders	8,252	12,100	(16,752)	3,600
The Innovation Research Project	92,800	68,700	(7,320)	154,180
Penile Cancer Peer Support	-	8,500	(7,500)	1,000
Education and Awareness	5,000	58,950	(30,295)	33,655
Student Study and Travel Scholarships	6,729	-	(2,000)	4,729
Roadshows	2,860	42,871	(38,871)	6,860
Robert Lane Tissue Bank	-	42,800	(42,800)	-
Young Person's Testicular Cancer Project	3,228	-	(3,228)	-
City of London Corporation	10,000	-	(10,000)	-
Total restricted	<u>161,314</u>	<u>400,594</u>	<u>(317,088)</u>	<u>244,820</u>
Total funds	<u>440,280</u>	<u>841,808</u>	<u>(740,252)</u>	<u>541,836</u>

General funds are unrestricted funds available for use at the Trustees' discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

15. Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2023 £
Fixed Assets	3,340	-	3,340
Current Assets	376,490	338,538	715,028
Creditors due within one year	(81,229)	-	(81,229)
Net assets at 30 September 2023	298,601	338,538	637,139
Prior year analysis of net assets between funds			
Fixed Assets	13,095	-	13,095
Current Assets	454,430	244,820	699,250
Creditors due within one year	(170,509)	-	(170,509)
Net assets at 30 September 2022	297,016	244,820	541,836

16. Related party transactions

Aggregate donations of £500 were received from trustees in the year ended 30 September 2023. (Year to 30 September 2022: £52,500).

17. Financial commitments

For the year ended 30 September 2023, the charity was committed to making the following future payments under non cancellable operating leases.

	Year ended 30 September 2023 Total £	Year ended 30 September 2022 Total £
<i>Land and buildings</i>		
Expiring within one year	15,637	14,184
Expiring within two to five years	-	-
	15,637	14,184

18. Capital commitments

At the year ended 30 September 2023, the charity had no capital commitments (2022: £9,204).

